 NEW YORK, June 7, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ , a novel therapeutic for the treatment of symptoms related to Alzheimers disease. The research will be led by Carla Yuede, PhD, Associate Professor of Psychiatry, and John Cirrito, PhD, Associate Professor of Neurology, at Washington University School of Medicine. 